Tyson Foods reported solid fiscal Q1 results, with earnings of $1.14 per share, beating estimates by $0.26. Read why I'm ...

Palantir's U.S. commercial revenue surged 64% YoY, driven by AIP technology, but faces intensifying competition and high ...

Xylem Inc.’s XYL fourth-quarter 2024 adjusted earnings of $1.18 per share beat the Zacks Consensus Estimate of $1.12. The ...

Operating income was $6.2 million in the first quarter of fiscal 2025, compared to $9.7 million in the prior year period. This led to net earnings in Q1 ’25 of $5.1 million, compared to $7.3 million ...

The property business gearing was 26% at the end of July 2024, well below the 60% covenant. The trust’s interest cover ratio was 1.9 times at the end of January 2024, versus a covenant of 1.5 times.

Pro Medicus is in a strong financial position. As of June 2024, it had AUD 155 million in net cash, and we forecast the company to continue holding net cash over our explicit 10-year forecast period.

CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

MPLX LP (NYSE:MPLX) reported fourth quarter earnings and revenue that surpassed analyst expectations, leading to a modest ...

Reports Q4 revenue $2.3B, consensus $2.18B. “The team delivered a strong fourth quarter to close a record-breaking year for Xylem (XYL),” said ...

France's BNP Paribas reported a forecast-beating jump in net income in the fourth quarter as its investment bankers rode a surge in trading activity, but the lender lowered a key profit target for ...

Pfizer reported robust fourth-quarter 2024 earnings, exceeding expectations in both revenue and adjusted earnings.